|






| |
Toutes
les associations et organismes oeuvrant pour une meilleure diffusion de
l'information peuvent disposer gratuitement d'une page dans le site Pneumopathie-atypique.net
Contactez nous |

| |
Ce site d'informations ne peut en aucun cas être considéré
comme un prescripteur ou comme un médecin : Toutes les informations
présentes sur le site vous permettent de mieux comprendre la maladie
mais se cantonnent strictement à un caractère informatif d'ordre
général.
En cas de problèmes de santé, consulter un médecin.
|
|
 |
DOCUMENTS
SUR LA PNEUMOPATHIE ATYPIQUE
| 01 |
Extrait
de l'article de Julie Louise Gerberding, Directrice du CDC (Atlanta)
. |
Extrait de
l'article de Julie Louise Gerberding, Directrice du CDC (Atlanta) .
During this
two-month period,the World Health Organization (WHO) has coordinated an
international investi- gation that has produced unprecedented scientific
and epidemiologic discoveries with unprecedented speed....On March 14,the
Centers for Disease Control and Prevention (CDC)activated its emergency
operations center ...
Over the next two weeks,the machinery to discover and characterize the
pathogen was set in full motion by scientists .....
Within days,sequences of the coronavirus polymerase gene were compared
with those of previously characterized strains,and scientists were able
to say with confidence that this virus was distinct from all known human
pathogens.In addition, serum from patients with SARS was evaluated to
detect antibodies to the new coronavirus,and serocon- version was documented
in several patients with appropriate acute-and convalescent-phase specimens
in laboratories at the CDC and elsewhere. Coronavirus has not been proved
to be the cause of SARS,but strong supportive evidence is accumulating....
Even more impressive than the speed of scientific discovery in the global
SARS outbreak is the almost instantaneous communication and information
exchange that has supported every aspect of the response...The international
media have also played an around-the-clock part in communicating breaking
news to the public by television,radio,print publications,and the Internet.
.
However,
despite these advances,a very sobering question remains -are we fast
enough?Can we prevent a global pandemic of SARS?
The epidemic is progressing rapidly in many parts of Asia.The situation
in mainland China is not entirely clear,but the available information
strongly suggests that there is ongoing transmission in at least some
provinces.The epidemic is still expanding in Hong Kong, despite heroic
measures on the part of the government to curtail its spread.Clusters
of cases in com- munity settings such as hotels and apartment buildings
in Hong Kong demonstrate that transmission can be extremely efficient.Likewise,very
high attack rates among health care workers in Hanoi,Vietnam,and in hospitals
in Hong Kong document the highly contagious nature of this virus.
Many household contacts have become ill.Concern is mounting about the
potential for spread in schools,the workplace,airplanes,and other crowded
areas.New cases among travelers from affected areas continue to emerge
and have led to infections in household contacts and health care personnel
in many countries,including the United States and Canada. The epidemic
of SARS is apparently only months old,and it is entirely too soon to
predict its ultimate scope or magnitude.Epidemiologic evidence indicates
that the transmission of SARS is facilitated by face-to-face contact,and
this still appears to be the most common mode of spread. Some evidence
suggests that a few persons may be especially infectious and that most
others are less likely to serve as sources of infection,but this concept
is still speculative. Airborne transmission may have a role in some settings
and could account for the extensive spread within buildings and other
confined areas that has been observed in some places in Asia. Certainly,
airborne transmission will make containment of the epidemic much more
challenging. If the new coronavirus proves to be the cause of SARS, fomite
or other modes of transmission could also be relevant,since coronaviruses
can survive on contaminated objects in the environment for at least a
few hours and have been isolated from the stool of some animals. Despite
our long experience with other viral respiratory infections,we have no
proven,successful population-based strategy for their prevention.Even
when we have an effective vaccine,as in the case of influenza,annual infection
rates and attributable mortali- ty remain very high.If SARS transmission
evolves to mimic that of influenza,containment may well be impossible
without vaccination,prophylaxis,or treatment. There is reason to be
optimistic about future control measures.Vaccines are successful in preventing
coronavirus infection in animals,and the development of an effective vaccine
against this new coronavirus is a realistic possibility.Likewise, novel
antiviral agents,antiviral drugs in development,or existing licensed drugs
could be found to provide effective prophylaxis or treatment.But can we
make these products available fast enough to prevent an extensive global
outbreak?Recent experience with the advances in measures against bioterrorism
suggests that the pace of development can be dramatically accelerated.However,
potential rate-limiting steps include the development of suitable animal
models to demonstrate efficacy,the time necessary to demonstrate the safety
of any new product in adults and children,and the time and resources needed
to increase production to meet global market needs. The emergence of SARS
presents formidable global challenges.If we are extremely lucky,the ep-
idemic will be curtailed,develop a seasonal pattern that will improve
prospects for regional containment,or evolve more slowly than it has in
this early stage.If the virus moves faster than our scientific, communications,and
control capacities,we could be in for a long,difficult race.In either
case,the race is on.The stakes are high.And the outcome cannot be predicted.
From the Centers for Disease Control and Prevention,Atlanta.
This article was published at www.nejm.org
on April 2,2003.
|
 |
 |